October 30, 2023/FSDH Update
Fidson Healthcare Plc (“Fidson” or the “Company”) Series 5 & 6 Commercial Paper (“CP”) of up to ₦5 Billion under its ₦10 billion CP Programme (the “Programme”) is Now Open and scheduled to close on Monday, 6 November 2023. Fidson is one of the leading pharmaceutical manufacturing companies in Nigeria. The Company is engaged in the manufacturing, marketing, and sales of pharmaceutical and healthcare products in Nigeria and West Africa. Fidson currently has over 250 duly registered pharmaceutical brands, across different therapeutic areas, in the Nigerian market. The Company has recorded impressive growth over the years, with a year-on-year increase in revenue and profit-after-tax of 32% and 13%, respectively for the year ended 2022. For the six months ending 30 June 2023, the Company recorded ₦25.6 Billion in sales, a 25% increase over ₦20.4 Billion recorded in the previous year. Fidson has previously accessed funding through the Capital markets, having issued a ₦5 Billion 269- day Commercial paper in March 2023, ₦3 Billion 270- day Commercial paper in June 2022, ₦2.15 Billion 90-day Commercial Paper in December 2021, ₦4.5 Billion 270-day Commercial Paper in March 2021, a ₦2.3 Billion Rights Issue in July 2019, and a ₦2.0 Billion five-year Secured Fixed Rate Corporate Bond in November 2014. Please see below the indicative terms of the proposed offer: |
 |
Please see the link to the supporting documents for your review and consideration:
|
